Europe Multiple Myeloma Market Size, Share & Industry Trends Analysis Report By End User, By Disease Type (Active Multiple Myeloma and Smoldering Multiple Myeloma), By Drug Type, By Country and Growth Forecast, 2023 - 2029

Europe Multiple Myeloma Market Size, Share & Industry Trends Analysis Report By End User, By Disease Type (Active Multiple Myeloma and Smoldering Multiple Myeloma), By Drug Type, By Country and Growth Forecast, 2023 - 2029

The Europe Multiple Myeloma Market would witness market growth of 9.1% CAGR during the forecast period (2023-2029).

An increase in R&D activity is contributing to expanding the multiple myeloma market. The growth of the multiple myeloma market will benefit from these opportunities. In addition, an increase in the number of drugs that are both released and approved will further propel the growth rate of the market. Monoclonal antibodies (mAbs), like Empliciti and Darzalex, will act as a major opportunity for the market's growth because they will not only give patients with multiple myeloma a new therapeutic option, but they will also help patients experience fewer relapses, extending the effectiveness of Revlimid and Velcade treatments.

In addition, these patients will also have access to Kyprolis and Ninlaro, two second-generation protease inhibitors, broadening their treatment options. This will affect the market and industry, currently dominated by the proteasome inhibitor Velcade and the immunomodulator Revlimid. Also, growing investments in cutting-edge technologies and a rise in new markets will create more favorable conditions for expanding the multiple myeloma market over the forecast period.

The prevalence of multiple myeloma has been continuously rising in Germany over the past few years, which has increased the demand for cutting-edge therapies. The prevalence of multiple myeloma is higher in older persons, and as Germany's population ages, there will likely be greater demand for medicines for the disease. The market is expanding due to substantial developments in creating novel treatments for multiple myelomas, such as immunomodulatory medicines and monoclonal antibodies. The German healthcare system offers advantageous reimbursement rules for cancer therapies, including medications for multiple myeloma, which is assisting in the market's expansion.

The Germany market dominated the Europe Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,529.5 Million by 2029. The UK market is anticipated to grow at a CAGR of 8.2% during (2023 - 2029). Additionally, The France market would exhibit a CAGR of 9.9% during (2023 - 2029).

Based on End User, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.

Scope of the Study

Market Segments covered in the Report:

By End User

Hospitals
Clinics
Others
By Disease Type

Active Multiple Myeloma
Smoldering Multiple Myeloma
By Drug Type

Protease Inhibitors
Monoclonal Antibody
Chemotherapy
Others
By Country

Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Companies Profiled

Novartis AG
Bristol Myers Squibb Company
Amgen, Inc.
AbbVie, Inc.
Sanofi S.A.
Johnson & Johnson
Baxter International, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceuticals Industries Ltd.
Pfizer, Inc.
Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free